Study | Intervention | Application modality | Additional anesthesia | Type of surgery | Sponsoring/Funding | |
Liposomal bupivacaine | Bupivacaine HCl | |||||
Alijanipour et al 21 | 266 mg liposomal bupivacaine* | 50 mg bupivacaine hydrochloride* | PAI | Spinal anesthesia (15 mg bupivacaine hydrochloride) | TKA | No financial funding |
Alter et al 22 | 133 mg liposomal bupivacaine+50 mg bupivacaine hydrochloride | 100 mg bupivacaine hydrochloride | Local infiltration injection site | General anesthesia | Distal radius repair | Study was supported through an unrestricted educational grant from Pacira Pharmaceuticals |
Barron et al 23 | 266 mg liposomal bupivacaine | 50 mg bupivacaine hydrochloride | Infiltration at fascial level around the planned throcar site | General anesthesia | Laparascopic hysterectomy | No financial funding |
Bramlett et al 24 | 133 and 266 mg liposomal bupivacaine hydrochloride | 150 mg bupivacaine hydrochloride* | Wound infiltration | General anesthesia | TKA | Support by Pacira Pharmaceuticals, one author is paid employe by Pacira Pharmaceuticals |
Bultema et al 25 | 53.2 mg liposomal bupivacaine | 20 mg bupivacaine hydrochloride* | Wound infiltration | Inferior alveolar nerve block (lidocaine) | Dental intervention | No financial funding |
Dale et al 27 | 266 mg liposomal bupivacaine | 75 mg bupivacaine hydrochloride | Trapeziometacarpal suspension arthroplasty: subcutaneous infiltration and injection into the neo-joint; proximal row carpectomy: subcutaneous injection | General anesthesia | Trapeziometacarpal suspension arthroplasty or proximal row carpectomy | The liposomal bupivacaine used in the study was donated by Pacira Pharmaceuticals |
Glenn et al 26 | 53.2 mg liposomal bupivacaine | 20 mg bupivacaine hydrochloride* | Buccal infiltration | Local anesthesia (lidocaine) | Dental intervention | Supported by a research grant from the American Association of Endodontists Foundation |
Ha et al 28 | 266 mg liposomal bupivacaine | 75 mg bupivacaine hydrochloride* | TAP | General anesthesia | Abdominally based autologous microvascular breast reconstruction | Grant from hospital foundation, no industrial sponsorship, one author received unrelated founding |
Haas et al 29 | 66, 199, 266 mg liposomal bupivacaine | 75 mg bupivacaine hydrochloride* | Perianal tissue infiltration | General anesthesia | Hemorrhoidectomy | Supported by Pacira Pharmaceuticals |
Hutchins et al 30 | 133 mg liposomal bupivacaine | 75 mg bupivacaine hydrochloride* | Subcostal TAP | General anesthesia | Hysterectomy | Grant funding from Pacira Pharmaceuticals |
Hutchins et al 31 | 133 mg liposomal bupivacaine | 75 mg bupivacaine hydrochloride* | Subcostal TAP | General anesthesia | Laparoscopic donor nephrectomy | Consultant for Pacira Pharmaceuticals |
Iwanoff and Salamon32 | 266 mg liposomal bupivacaine | 150 mg bupivacaine hydrochloride+500 mg lidocaine | Infiltration of the vaginal subepithelial tissue | General anesthesia | Midurethral sling surgery | No financial funding |
Knight et al 33 | 266 mg liposomal bupivacaine | Upto 150 mg bupivacaine hydrochloride | Injection of the laparoscopic port sites | General anesthesia | Laparoscopic urological surgery | No financial funding |
Knudson et al 34 | 266 mg liposomal bupivacaine | 150 mg bupivacaine hydrochloride* | Subfascial peri-incisional injection | General anesthesia | Elective colon resection | No financial funding |
Motakef et al 35 | 133 mg liposomal bupivacaine | 50 mg bupivacaine hydrochloride* | Field block of breast pocket | General anesthesia | Breast reconstruction | Funding from Plastic Surgery Foundation |
Nadeau et al 36 | 133 mg liposomal bupivacaine | 50 mg bupivacaine hydrochloride* | Infiltration of breast pocket | General anesthesia | Breast augmentation | Funding by a resident research grant from Riverside Methodist Hospital |
Perets et al 37 | 266 mg liposomal bupivacaine+100 mg bupivacaine* | 150 mg bupivacaine hydrochloride* | PAI | General anesthesia | Total hip replacement | Research support from Pacira Inc |
Premkumar et al 38 | 266 mg liposomal bupivacaine | 100 mg bupivacaine hydrochloride | Local injection into graft harvest site and portal sites | General anesthesia | Anterior cruciate ligament reconstruction | No financial funding |
Schroer et al 39 | 266 mg liposomal bupivacaine+75 mg bupivacaine hydrochloride | 150 mg bupivacaine hydrochloride | PAI | Spinal or general anesthesia | TKA | No financial funding |
Schumer et al 40 | 266 mg liposomal bupivacaine+75 mg bupivacaine hydrochloride | Bupivacaine hydrochloride (dose not stated) | Local wound infiltration | Spinal anesthesia | TKA | No financial funding |
Vandepitte et al 41 | 133 mg liposomal bupivacaine+12.5 mg bupivacaine hydrochloride | 37.5 mg bupivacaine hydrochloride | Interscalene plexus block | General anesthesia | Major shoulder surgery | Funding by Pacira Pharmaceuticals |
Wong et al 42 | 266 mg liposomal bupivacaine+75 mg bupivacaine hydrochloride | 125 mg bupivacaine hydrochloride | TAP | General anesthesia | Laparoscopic Roux-en-Y gastric bypass, sleeve gatsrectomy, sleeve to bypass conversion | No financial funding |
Zlotnicki et al 43 | 266 mg liposomal bupivacaine | 100 mg bupivacaine hydrochloride | PAI | Spinal anesthesia | TKA | No financial funding |
*With epinephrine.
PAI, periarticular injection; TAP, transversus abdominis plane block; TKA, total knee replacement.